Therapies that effectively target tissue injury are lacking in chronic kidney disease (CKD). Researchers show that in a mouse model of kidney injury, continuous cysteamine treatment after injury significantly reduced the severity and extent of fibrosis. Furthermore, treatment with cysteamine reduced myofibroblast proliferation and mRNA levels of extracellular matrix proteins. These results suggest cysteamine could have antifibrotic properties and has potential as a new therapy in CKD.
ORIGINAL RESEARCH PAPER
Okamura, D. M. et al. Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD. J. Am. Soc. Nephrol. doi:10.1681/ASN.2012090962
Rights and permissions
About this article
Cite this article
Cysteamine treatment shows evidence of antifibrotic activity. Nat Rev Nephrol 9, 626 (2013). https://doi.org/10.1038/nrneph.2013.189
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.189